Aeglea BioTherapeutics (AGLE) Stock

Are you looking for the best penny stocks to watch right now? With all of the excitement in the stock market today, you're not alone.

With the uptick of volatility in the stock market today, there's no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there's a significant global catalyst, cheap stocks are usually a topic of discussion.

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.

Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.

Aeglea BioTherapeutics (NASDAQ: AGLE ) stock is undergoing a massive rally on Thursday after it announced its acquisition of Spyre Therapeutics. Aeglea BioTherapeutics has completed its acquisition of the privately-held biotechnology company.

Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.

Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.

Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.